title: [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
authors.affiliation: IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France.
authors.forename: Christel
authors.initials: C
authors.lastname: Larbouret
authors.affiliation: Department of biological regulation, Weizmann Institute of Science, Rehovot, 76100, Israël.
authors.forename: Nadège
authors.initials: N
authors.lastname: Gaborit
authors.affiliation: IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France.
authors.forename: Marie-Alix
authors.initials: MA
authors.lastname: Poul
authors.affiliation: IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France.
authors.forename: André
authors.initials: A
authors.lastname: Pèlegrin
authors.affiliation: IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Chardès
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000235:genetics / Q000502:physiology; D006801:Humans; D058990:Molecular Targeted Therapy; D005810:Multigene Family; D009154:Mutation; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects; D054875:Ubiquitination / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; C581292:ERBB3 protein, human; D066246:ErbB Receptors; D020893:Receptor, ErbB-3